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BACKGROUND:  We  have  previously  shown  that  the
calcium-binding  protein  MRP-14  secreted  by  neu-
trophils mediates the antinociceptive response in an
acute  inflammatory  model  induced  by  the  intra-
peritoneal injection of glycogen in mice.
Aim:  In  an  attempt  to  broaden  the  concept  that
neutrophils and MRP-14 controls inflammatory pain
induced by different type of irritants, in the present
study, after demonstrating that carrageenan (Cg) also
induces atinociception in mice, we investigated the
participation of both neutrophils and MRP-14 in the
phenomenon.
Methods:  Male  Swiss  mice  were  injected  intraper-
itoneally with Cg and after different time intervals,
the pattern of cell migration of the peritoneal exudate
and the nociceptive response of animals submitted to
the writhing test were evaluated. The participation of
neutrophils and of the MRP-14 on the Cg effect was
evaluated  by  systemic  inoculation  of  monoclonal
antibodies anti-granulocyte and anti-MRP-14.
Results: Our results demonstrate that the acute neu-
trophilic  peritonitis  evoked  by  Cg  induced  anti-
nociception  2,  4  and  8h  after  inoculation  of  the
irritant.  Monoclonal  antibodies  anti-granulocyte  or
anti-MRP-14  reverts  the  antinociceptive  response
only 2 and 8h after Cg injection. The antibody anti-
MRP-14 partially reverts the antinociception observed
after 4h of  Cg  injection  while the anti-granulocyte
antibody enhances this effect. This effect is reverted
by simultaneous treatment of the animals with both
antibodies. After  4h  of  Cg  injection  in  neutrophil-
depleted mice a significant expression of the calcium-
binding  protein  MRP-14  was  detected  in  the  cyto-
plasm of peritoneal macrophages. This suggests that
the enhancement of the effect observed after treat-
ment with the anti-neutrophil antibody may be due to
secretion of MRP-14 by macrophages. It has also been
demonstrated  that  endogenous  opioids  and  gluco-
corticoids  are  not  involved  in  the  antinociception
observed at the 4th hour after Cg injection.
Conclusion: These data support the hypothesis that
neutrophils and the calcium-binding protein MRP-14
are participants of the endogenous control of inflam-
matory  pain  in  mice  despite  the  model  of  acute
inflammation used.
Key words: MRP-14;  neutrophils;  antinociception;  carra-
geenan; mice.
Introduction
Inflammation  is  initiated  by  release  of  pharmaco-
logical agents and consequent recruitment of leuko-
cytes from  the blood stream to the injured tissues.
These events  involve  expression of adhesion mole-
cules  on  the  vascular  endothelium  and  adherence,
diapedesis, and emigration of leukocytes to the extra
vascular compartments.1,2
In most of the animal models of inflammation, a
high  proportion  of  neutrophils  and  a  low  propor-
tion  of  monocytes  promptly  arrive  at  the  focus  of
injury.  Besides  its  typical  morphology,  neutrophils
can  be  characterized  by  the  high  expression  of
the  calcium-binding  proteins  MRP-8  and  MRP-14.3
These proteins were isolated, sequenced, and their
genes  cloned  in  an  attempt  to  characterize  the
migration  inhibitory  factor  (MIF)  that  accounts  for
their  denomination  as  MIF-related  proteins.4,5
These  proteins  belong  to  the  S-100  protein  family
and  form  heterodimeric  complexes  called
calprotectin.6,7
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and heavy chain,8,9 calgranulin A and B,10,11 p8 and
p1412 respectively, and cystic fibrosis antigen.13 The
expression of these proteins is restricted to a specific
stage of myeloid differentiation, since both proteins
are expressed in  circulating  neutrophils and mono-
cytes but  are absent in  normal tissue macrophages
and lymphocytes.14,15 MRP-8 and MRP-14  comprise
45  and  1%  of  the  total  proteins  in  the  cytosol  of
neutrophils  and  monocytes  respectively.16 Under
inflammatory conditions and/or upon calcium mobili-
zation they are translocated from the cytosol to the
cytoskeleton and to cell plasma membrane.17,18 It has
been demonstrated that both proteins are secreted by
activated monocytes via a tubulin and Protein Kinase
C-dependent pathway.19 Another relevant character-
istic  of  these proteins  is  that they  are  highly  con-
served,  presenting  60–80%  homology  between
humans,  rat,  and  mouse.16,20 Recently,  it  has  been
demonstrated that the heterodimer of these proteins
binds arachidonic acid with high affinity.21,22
A novel function recently described for MRP-14 is
its ability to regulate neutrophil adhesion to fibrino-
gen  via  b2 integrin  (CD11b/CD18,  Mac-1).23 MRP-
8/14 complex is found in high concentrations in body
fluids  of  patients  with  acute  and  chronic  diseases
such as chronic bronchitis, cystic fibrosis and rheuma-
toid arthritis,24–26 suggesting a possible extracellular
role for these proteins. In this context, it has been
reported a marked anti-inflammatory effect of MRP-
8/14 complex in a model of adjuvant-induced arthritis
in the rat.27Additionally, it was demonstrated that the
calcium-binding  protein MRP-14  but not the MRP-8
deactivates activated peritoneal macrophages.28
It is generally accepted that neutrophils are at the
forefront of an inflammatory response. These cells act
not only as effector cells but also as regulatory cells in
inflammatory reactions through the production of a
variety  of  protein  factors  including  proteolytic
enzymes  and  cytokines.29–31 On  the  other  hand
macrophages, considered as the body’s alarm cell,32
also  secrete  a  large  variety  of  chemical  mediators
released during the inflammatory response.33 It is also
well established that mediators released by these cells
can interfere in the pathophysiology of inflammatory
pain.34,35
Among  these  chemical  mediators  witch  regulate
the  inflammatory  nociceptive  response  are TNF-a,
prostaglandins, interleukin (IL)-1, IL-6, IL-8 and oth-
ers.36–37 Otherwise,  it  has  also  been  demonstrated
the  participation of interleukins  such  as IL-4,  IL-10
and IL-13 on inhibitory mechanisms of inflammatory
hyperalgesia.38–40 In this context, results obtained in
our laboratory demonstrated that the calcium-binding
protein  MRP-14  induces  an  antinociceptive  effect
when evaluated in a model of inflammatory pain in
the mouse.41 We have also demonstrated that MRP-14
released by neutrophil mediates the inhibition of pain
response  in  a  model  of  neutrophilic  peritonitis
induced  by  glycogen  in  mice.41 In  this  paper  we
demonstrate that the intraperitoneal inoculation of a
carrageenan  (Cg)  solution  in  mice  also  induces
antinociception. Thus, the aim of  this work was to
investigate the participation of both neutrophils and
MRP-14 on Cg-induced antinociception, in an attempt
to broaden the hypothesis that neutrophils, via MRP-
14,  is  an  endogenous  antinociceptive  component




Outbreed male mice from the Swiss strain, weighing
20–25g,  were used throughout this study. The ani-
mals were maintained under controlled light (12/12
hours) and temperature (22±2°C) with free access to
food  and  water. Throughout  the  experiments,  the
animals  were  managed  using  the  principles  and
guidelines for the care of laboratory animals accord-
ing to Zimmermann.42
Carrageenan-induced peritonitis
Carrageenan  (Sigma,  MO,  USA)  was  prepared  in
sterile saline (300mg/0.2ml per animal). Mice were
injected intraperitoneally with 0.5ml of this solution
and killed in an ether chamber after 0.5, 2, 4, 8, 12, 24
and 48h. The peritoneal exudate was collected and
the total and differential counts of leukocytes deter-
mined.  Controls  were  injected  with  sterile  saline.
Animals injected with  Cg  solution  were submitted,
after different time intervals, to the nociceptive test.
Nociception evaluation by the writhing test
The  mouse  writhing  test  used  was  based  on  the
method of Koster et al.43 The abdominal contortions
resulting from intraperitoneal (i.p.) injection of acetic
acid (0,6%; Merck, Darmstadt, Germany) at a dosage
of  60mg/Kg  (v/v)  consist  of  a  contraction  of  the
abdominal  muscles  together  with  the  stretching  of
the hind limb. The number of abdominal contortions
was  counted cumulatively  over  a  period  of  20min
after acetic acid injection. The antinociceptive activity
was expressed as the reduction in number of abdomi-
nal  contortions  in  treated  as  compared  to  control
animals (injected only with acetic acid).
Monoclonal antibodies (mAbs)
RatmAb (IgG2b) anti-granulocyte (anti-GR-1), an anti-
body  that  depletes  mice  of  mature  granulocytes,44
and ratmAb (IgG) anti-murine MRP-14 (EPM–1B4D3)
were used. The antibody anti-Gr-1 (0.25mg of protein
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i.p. injection of Cg. ThemAb anti-MRP-14 (0.4mg of
protein in 100ml of saline) was injected intravenously
5min before the phlogistic agent injection.
Immunohistochemistry
The  animals  injected  or  not  with  anti-granulocyte
antibody were killed in an ether chamber 4h after Cg
injection. The peritoneal exudate was collected with
5ml of RPMI media and the peritoneal cells counted
and concentrated to 2 ´ 106 cell/150ml in RPMI media.
Experiments  were  performed  using  24-well  plates
(Costar, NY, USA) with sterile round glass coverslips in
the bottom. The plates were incubated for 1h at 37°C
followed  by  lavage  with  phosphate-buffered  saline
(PBS) and fixation in Millonig fixative for 24h. In the
moment of the assay, plates were washed for three
times  with  PBS  and  incubated  with  glycine  buffer
(50 mM)  for  30min  at  room  temperature.  Subse-
quently, the buffer was discarded, the wells washed
with PBS and the cell membranes permeabilized with a
Triton X-100 solution (0.02%) for 5min. All incubations
were done at room temperature and PBS was used for
washing  the  wells  after  each  step.  Endogenous
peroxidase was quenched with 0.3% H2O2 in PBS for
50min. The cells were then incubated with normal
horse  serum  in  PBS  for  1h  and  overlaid  with  the
primary antibody (mAb anti-MRP-14) at 4°C overnight.
Thereafter they were incubated with biotinylated goat
anti-rat IgG  secondary antibody  (Sigma,  MO,  USA),
followed by streptoavidin peroxidase complex (Sigma,
MO, USA) for 30min. The material was stained with
10mg of diaminobenzidine tethahydrochlorid (DAB;
Sigma,  MO,  USA)  with 0.03%  H2O2 in Tris-buffered
saline (0,05M; pH 7,6). After staining, the cells were
washed in tap water and counterstained with Harry’s
hematoxilin (Merck, Darmstadt, Germany) for 40 sec.
Finally,  the  cells  were  dehydrated and  mounted  in
Entellan (Merck, Darmstadt, Germany).
Participation of opioids
Mice were injected with naloxone chloridate (Rhodia,
S˜ ao  Paulo,  Brasil),  a  universal  opioid  antagonist,
prepared  in  sterile  saline  (1mg/Kg  per  animal).
Animals were injected with 200ml of this solution by
subcutaneous route 15min before the i.p. injection of
acetic acid in animals pretreated with Cg.
Participation of glucocorticoids
Mice were injected with metyrapone (Ciba-Geigy, S˜ ao
Paulo, Brazil), dissolved in sterile saline. Metyrapone
blocks the synthesis of glucocorticoids without caus-
ing a typical deficiency of mineralocorticoids.45 Two
daily  doses  of  30mg/Kg  each  were  given  intra-
peritoneally  at  12h  intervals  for  5  days.46 Control
animals  received  the  same  amount  of  saline.  Cg
injection was made 2h after the administration of the
last dose metyrapone and the writhing test evaluated
4h after injection of the phlogistic agent.
Statistical analysis
Results are expressed as mean ± standard errors of
means (S.E.M.) and were compared by the Student9st
test or by analysis of variance47 followed by Duncan9s
test.48 A probability level of less than 0.05 was taken
as significant (p < 0.05).
Results
Leukocyte migration induced by carrageenan
Considering that the protein MRP-14 is expressed in
large amounts in the cytosol of neutrophils16 and that
this protein mediates an antinociceptive effect in  a
neutrophilic  peritonitis  induced  by  glycogen,41 we
decided to investigate if this effect was restricted to
the glycogen model or if it could be evidenced in an
Neutrophils and MRP-14 mediate antinociception
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FIG. 1. Kinetic of leukocyte influx to peritoneal cavity of mice
after  i.p.  injection  of  a  carrageenan  (Cg)  solution
(300mg/0,2ml  per  animal).  Number  of  neutrophils  in  the
peritoneal cavity after the irritant injection (A). Number of
mononuclear  cells  after  Cg  injection  (B).  The  results  are
expresses in absolute numbers obtained in relation to the
total number of collected cells. Data represent mean values
±S.E.M.  for  8–16  animals  for  each  experimental  time.
*Significantly different from mean values of saline group (p
< 0.05).another  model  of  neutrophilic  peritonitis.  For  this
purpose  a  model  of  neutrophilc  peritonitis  was
established using Cg as the phlogistic agent.
Results show that the i.p. injection of this irritant
evokes significant alterations in the pattern of circu-
lating leukocytes. The total number of neutrophils in
the peritoneal cavity of animals injected with Cg was
significantly higher than controls. The maximal num-
ber  of  polymorphonuclear  cells  in  the  peritoneal
cavity  was  observed  8h  after  the  irritant  injection
(Fig. 1A). On the other hand, a marked increase in the
number of mononuclear cells 8h after the phlogistic
agent injection was observed (Fig. 1B).
Carrageenan-induced neutrophilic peritonitis
and antinociception evaluated by the writhing
test
To  investigate  a  possible  correlation  between  the
influx of neutrophils to the peritoneal cavity and a
possible antinociceptive effect of the irritant, animals
were submitted to the writhing test after Cg injection.
As show in Figure 2, mice injected with Cg and tested
after 2, 4 or 8h in the pain test showed a significant
decrease  in  the  number  of  abdominal  contortions
when  compared  with  animals  previously  injected
with saline or with acetic acid alone. (±30% inhibition
in all the times tested).
Effect ofmAb anti-granulocyte on
antinociception in the carrageenan-induced
peritonitis
To investigate whether the analgesic effect observed
was  due  to  the  presence  of  neutrophils  in  the
inflammatory  site,  depletion  of  these  cells  with  a
specificmAb was used. Animals pretreated withmAb
anti-granulocyte (anti-Gr-1, 0.25mg, i.p.), 36h before
the i.p. injection of Cg, showed a 99% reduction in
the  total  number  of  neutrophils  in  the  peritoneal
exudate (data not shown). Depletion of neutrophils,
totally  reverted  the  antinociceptive  response  only
after  2  and  8h  of  the irritant injection (Fig.  3).  In
contrast, this treatment enhanced the antinociceptive
effect  at  4h  after  Cg  injection. The  treatment  of
animals with non-related rat IgG2b did not influence
the antinociceptive effect observed in any times after
the irritant injection (Fig. 3).
Effect ofmAb anti-MRP-14 on the
antinociceptive response induced by
carrageenan
To investigate whether MRP-14 was implicated in the
antinociception  observed,  mice  were  treated  with-
mAb  anti-MRP-14.  The  animals  were  treated  with
40mg of protein in 50ml saline, i.v., 5min before the
i.p. injection of Cg. This treatment completely abol-
ished  antinociception  detected 2  and  8h  after  the
irritant  injection  (Fig.  4).  However,  this  treatment
only partially reverted antinociception observed after
4h of Cg injection. Treatment of animals with non-
related rat IgG had no effect in the antinociceptive
effect induced by this irritant (Fig. 4).
Simultaneous treatment of the animals with
anti-granulocyte and anti-MRP-14mAbs
Once  the  depletion  of  neutrophils  enhances  the
antinociceptive response when the test were applied
4h  after  Cg  injection,  we  decided  to  evaluate  the
response of the animals in the absence of neutrophils
R. L. Pagano et al.
206 Mediators of Inflammation · Vol 11 · 2002
FIG. 2. Effect of  carrageenan (Cg) on painful sensibility of
mice evalued in the writhing test. The test was applied in
different times after the i.p. injection of Cg (300mg/0,2ml per
animal). Controls were injected only with acetic acid. Values
represent the mean ±S.E.M. of 8–16 animals for each group.
*p <  0.05  in  comparison  with  values  obtained  in  control
animals.
FIG. 3. Effect ofmAb anti-granulocytes (anti-Gr–1) on anti-
nociception  induced by  carrageenan (Cg)  in  animals  sub-
mitted to the writhing test. ThemAb anti-Gr–1 was injected
36h  before  the  i.p.  injection  of  Cg  and  2,  4  or  8h  later
submitted to  the writhing test.  Animals injected with non
relatedmAb  were  also  evaluated.  Controls  were  injected
only with acetic acid. Values represent the mean ±S.E.M. of
8–16 animals for each group. *p < 0.05 in comparison with
values obtained in control animals. **p < 0.05 in comparison
with the group treated with non relatedmAb + Cg.and  MRP-14.  Mice  were  inoculated  withmAb  anti-
granulocyte 36h before treatment with themAb anti-
MRP-14. The Cg solution was injected 5min after the
last treatment and the writhing test applied 4h after
the  phlogistic  agent  injection.  Results  show  that
treatment with both antibodies abolished the potenti-
alization of antinociceptive effect induced by Cg in
animals  pretreated  with  antibody  anti-granulocyte
(Fig. 5). Treatment of animals with non-relatedmAbs
did not alter the antinociceptive response evaluated
4h after the irritant injection (Fig.5).
Detection of MRP-14 in peritoneal cells of
animals inoculated with carrageenan
Considering that the treatment withmAb anti-MRP-14
was  able  to  revert  the  potentialization  of  anti-
nociceptive effect observed 4h after the Cg injection
in animals depleted of neutrophils, the expression of
MRP-14 in other inflammatory cells was evaluated by
imunocitochemistry.  Cells  were  obtained  from  the
abdominal  cavity  of  animals  4h  after  the  irritant
injection in mice pretreated or not with anti-granulo-
cytemAb. Cells obtained from the peritoneal exudate
4h  after  Cg  injection  were  positive  for  MRP-14
protein (Fig. 6A). However, when the test was made
with cells obtained from the peritoneal exudate 4h
after  the  irritant  injection  in  mice  depleted  of
neutrophils,  the  expression  of  MRP-14  was  sig-
nificantly  more  intense.  A  larger  number  of  cells
expressing  the  protein  in  their  cytoplasm  was
observed (Fig. 6B).
Neutrophils and MRP-14 mediate antinociception
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FIG. 4. Effect ofmAb anti-MRP-14 on antinociception induced
by carrageenan (Cg)  in animals submitted to the writhing
test. ThemAb anti-MRP-14 was injected 5min before the i.p.
injection of Cg and 2, 4 or 8h later submitted to the writhing
test.  Animals  injected  with  non-relatedmAb  were  also
evaluated.  Controls  were  injected  only  with  acetic  acid.
Values represent the mean ±S.E.M. of 8–16 animals for each
group.  *p <  0.05  in  comparison  with  values  obtained  in
control animals. **p < 0.05 in comparison with the group
treated with non relatedmAb + Cg.
FIG. 5. Effect of simultaneous treatment of the animals with
anti-granulocyte (anti-Gr-1) and anti-MRP-14 mAbs on anti-
nociception  induced by  carrageenan (Cg)  in  animals  sub-
mitted to the writhing test. ThemAb anti-Gr-1 was injected
36h  before  the  irritant  and  the  anti-MRP-14  was  injected
5min before the injection of Cg. The nociceptive test was
applied  4h  after  Cg  injection.  Animals  injected  with  non
relatedmAbs (nrmAbs) + Cg, nrmAb + anti-MRP-14 + Cg or
nrmAb + anti-Gr-1 + Cg were also evaluated. Controls were
injected with acetic acid. Values represent the mean ±S.E.M.
of 8–16 animals for each group. *p < 0.05 in comparison with
values obtained in control animals. **p < 0.05 in comparison
with animals treated with nrmAbs + Cg.
FIG. 6. Photomicrography of cells  obtained from  the peri-
toneal  cavity  of  animals  injected  with  Cg  4h  before  and
immunostained for the calcium-binding protein MRP-14 (A).
In B, cells obtained from the peritoneal exudate induced by
Cg injection in an animal previously depleted of neutrophils.
The expression of MRP-14 is more intense in this prepara-
tion. Optic microscopy (´ 100).Participation of endogenous opioids on
antinociception induced by carrageenan
Once themAbs anti-granulocyte and anti-MRP-14 did
not totally revert the antinociceptive effect induced
4h  after Cg injection, the possible  participation of
endogenous  opioids  in  the  phenomenon  was  eval-
uated. Animals were treated with naloxone chloridate
15min before the nociceptive test in mice pretreated
2 or 4h with Cg. Results demonstrated that opioid
peptides  did  not  influence  the  antinociception
induced by Cg (data not shown).
Participation of glucocorticoids in the
antinociceptive effect evoked by carrageenan
The participation of glucocorticoids, other possible
endogenous  factor  important  on  the  control  of
inflammatory  pain,  was  evaluated  during  antinoci-
ception induced 4h after Cg injection. Pretreatment
of  animals  with metyrapone, an  inhibitor  of  gluco-
corticoid  synthesis,  given  intraperitoneally  in  two
daily  doses  (12/12h)  for  5  days,  did  not  alter  the
antinociceptive  effect  induced  by  Cg  (data  not
shown).
Discussion
As  reported  in  the  literature,  chemical  mediators
released  during  the  inflammatory  process  are
endowed  with  the  property  of  inhibiting  pain
response. It has been shown that interleukins such IL-
4,  IL-10  and  IL-13  have  the  propriety  to  limit
inflammatory hiperalgesia by blocking the release of
pro-inflammatory  cytokines  by  inflammatory
cells.38–40 Furthermore,  it  was  demonstrated  by
Giorgi et al.41 that the calcium-binding protein MRP-
14  has  a  marked  antinociceptive  activity  in  an
inflammatory  pain  model  in  mice.  These  authors
brought evidences that neutrophils participate in the
control of inflammatory pain by secreting this protein
to the inflammatory milieu.41 Reports made by these
authors however,  were  limited  to  a  model  of  neu-
trophilic peritonitis induced by glycogen. It remains
then to be investigated whether neutrophils and MRP-
14 also control inflammatory pain in other models of
neutrophilic  peritonitis.  Here  we  demonstrate  that
similarly to the glycogen model, the intraperitoneal
inoculation  of  carrageenan  (Cg)  in  mice  not  only
induces a typical neutrophilic peritonitis but also a
marked antinociceptive response when animals were
tested in  a  model  of  inflammatory  pain. The  intra-
peritoneal injection of Cg solution 2, 4 or 8h before
the  acetic  acid  inoculation  induces  a  significant
antinociceptive response. Interesting to note that at
these times a large number of neutrophils were found
in the peritoneal cavity of the animals.
Based on  these  observations we  investigated the
possible  participation  of  neutrophils  and  of  the
calcium-binding protein MRP-14 in  the antinocicep-
tion induced by Cg. Results showed that treatment
of  animals  withmAbs  anti-granulocyte  or  anti-MRP-
14  before  the  phlogistc  agent  administration  were
able to totally revert antinociception observed 2 and
8h after Cg injection. Unexpectedly, pretreatment of
animals  with  anti-granulocytemAb  induced  an
increase  in  the  antinociceptive  effect  observed  4h
after the irritant injection. Further, the treatment of
animals with anti-MRP-14mAb partially reverted anti-
nociception observed 4h after the irritant injection.
Based  on  these  observations, animals  were  treated
with both antibodies previously to the evaluation of
the  antinociceptive  response.  The  association  of
antibodies anti-granulocyte and anti-MRP-14 induced
the  reversion  of  increase  in  antinociceptive  effect
observed when the animals were treated only with
the anti-granulocytemAb followed by Cg injection.
Amorim  Dias  (personal  communication,  2002)
have demonstrated that the intraperitoneal inocula-
tion glycogen in granulocyte-depleted mice induces
the  expression  of  MRP-14  in  the  cytoplasm  of
mononuclear  cells.  Similarly,  mononuclear  cells
obtained from  the peritoneal cavity of  neutropenic
mice  injected  with  Cg  also  express  the  calcium-
binding  protein  MRP-14.  Thus,  these  data  suggest
that the enhancement of the antinociceptive effect
observed  after  treatment  of  the  animals  with  anti-
granulocyte  antibody  might  be  due  to  secretion of
MRP-14 by macrophages. However, the mechanisms
by which neutrophil depletion induces macrophages
to  express  the  protein  MRP-14  remains  to  be
investigated.
Since antinociception observed 4h after Cg injec-
tion was not totally reverted by treatment of animals
with anti-MRP-14 antibody, other endogenous factors
could  be  involved  in  the  inhibition  of  pain  sensi-
bility. The liberation of endogenous opioids after Cg
injection might be one of these factors. It has been
largely demonstrated that endogenous opioids partic-
ipate  in  control  of  inflammatory  pain.49–50 Our
results however, showed that these mediators seems
not to be involved in the antinociception observed
at the 4th hour after Cg injection since treatment of
the animals with naloxone did not alter this effect.
As  has  been  demonstrated,  Cg  can  activate  the
hypothalamus-adrenal  axis  inducing  the  release  of
glucocorticoids by  the adrenal gland.51 As reported
in  the  literature,  this  hormone is  endowed  with  a
potent  anti-inflammatory  activity  and  consequently,
an  analgesic  property.52–54 Our  data  demonstrate
that  an  exacerbation  in  the  release  of  glucocor-
ticoids  by  adrenal  glands,  seems  not  to  influence
antinociception in this model since the inhibition of
glucocorticoid  synthesis  by  metyrapone administra-
tion  did  not  interfere  with  the  antinociceptive
R. L. Pagano et al.
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MRP-14 in the antinociceptive effect observed after
4h  of  Cg  injection  other  mechanisms  involved  in
this  effect  remains  to  be  elucidated.  In  summary,
results obtained in this work demonstrate that neu-
trophils  and  the  calcium-binding  protein  MRP-14
participate in the endogenous control of the inflam-
matory  pain  in  mice  despite  the  model  of  acute
inflammation used.
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